Business Context and Reporting Period
This Form 8-K was filed by Deep Medicine Acquisition Corp. on December 23, 2022. Although the request metadata identifies Trugolf Holdings, Inc., the filing text identifies Deep Medicine Acquisition Corp. as the registrant. The company was a special purpose acquisition company (SPAC) seeking to consummate an initial business combination.
Key Financial and Capitalization Information
- Stockholders holding 11,819,790 public Class A shares elected to redeem their shares for approximately $10.24 per share from the trust account.
- The filing reports that approximately “$121,034,649.60 million” would be removed from the trust account; this amount is internally unclear because of the stated “million” notation. Based on the reported per-share amount and share count, the filing indicates an aggregate redemption amount of approximately $121 million.
- Following redemptions, 830,210 public shares remained outstanding.
- All issued and outstanding Class B shares were converted into Class A shares on a one-for-one basis. Accordingly, 3,162,500 Class B shares were cancelled and 3,162,500 Class A shares were issued.
- The filing does not provide revenue, profit, cash flow, operating margin, debt, or liquidity metrics beyond the trust-account redemption information.
Material Changes and Corporate Actions
- Stockholders approved extending the deadline to complete an initial business combination from January 29, 2023 to July 29, 2023, or an earlier date determined by the board.
- The charter was amended to permit holders of Class B common stock to convert into Class A common stock on a one-for-one basis before the initial business combination.
- The Extension Amendment Proposal and Founder Share Amendment Proposal each received 12,906,590 votes for, 3 against, and no abstentions or broker non-votes.
- Tina Spires, HongLiang Ren, and John Chiang were re-elected as Class I directors.
Guidance, Outlook, Risks, and Unusual Items
The extension provides additional time to complete an initial business combination, but the filing does not identify a transaction target, provide financial guidance, or state that a transaction is assured. The substantial public-share redemptions materially reduced the remaining public share base and trust-account funds available for a potential transaction. The filing does not describe other contingencies or unusual items.
Investor Verification Items
- Confirm the registrant’s identity, because the filing names Deep Medicine Acquisition Corp., not Trugolf Holdings, Inc.
- Verify the exact trust-account redemption amount, given the filing’s unclear phrase “$121,034,649.60 million.”
- Assess whether the reduced trust balance and 830,210 remaining public shares affect the feasibility and funding of a future business combination.
- Confirm the amended July 29, 2023 business-combination deadline and the terms of the Class B-to-Class A conversion.
- Review Exhibit 3.1, the amendment to the Second Amended and Restated Certificate of Incorporation.